Hims & Hers Health, Inc. HIMS
20.26 USD -0.55 (-2.64%)
Nov 12, 2026, 1:14 PM EST
19.47 Day range 20.46
13.74 52-week range 40.99
- YTD
- -37.60%
- 1 year
- -48.08%
News
marketbeat.com Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off Even a nearly 9% rebound on Wednesday, Nov. 11, couldn't undo a punishing start to the week for Hims & Hers Health NYSE: HIMS. Shares had already plunged nearly 12% ahead of Monday evening's Q3…
seekingalpha.com Hims & Hers: Three Big Sacrifices Hims & Hers Health missed Q3 estimates, subscribers fell QoQ, and gross margin declined to a new low. To make matters worse, the company issued weak Q4 and FY2026 guidance. But most of the damage was…
zacks.com Hims & Hers Q3 Earnings Miss Estimates, Gross Margin Down HIMS shares dip nearly 3% after Q3 earnings and revenue miss, a sharp gross margin contraction and lower 2026 adjusted EBITDA guidance.
seekingalpha.com Hims & Hers Health: The Thesis Is Getting Shaky (Rating Downgrade) I'm downgrading Hims & Hers Health, Inc. to Hold, as Q3 raised more questions than it answered. Revenue grew 49% to $890M, but excluding Eucalyptus, growth was about 26%, and subscribers fell 100K…
247wallst.com Hims & Hers Climbs 6% Despite Five States Joining FTC Suit; Eli Lilly Dips, Novo Nordisk Holds Steady Hims and Hers is bouncing back after a brutal selloff, yet the legal heat keeps rising and its two biggest drug suppliers are sitting out the rally. What does the market see that the lawsuit…
benzinga.com Hims & Hers Under Fire: Five More States Join Federal Crackdown Over Alleged Privacy Violations The FTC and seven states expanded their lawsuit against Hims & Hers over deceptive recurring subscriptions and sensitive health data leaks.
benzinga.com Hims & Hers Week in Review: Q3 Miss, Weak Q4 Outlook, Huberman Joins Board Hims & Hers Health Inc. (NYSE:HIMS) had a busy week that included third-quarter results that missed estimates, a new board member in Andrew Huberman and a round of analyst price target changes.
benzinga.com Hims & Hers Week in Review: Q3 Miss, Weak Q4 Outlook, Huberman Joins Board Hims & Hers Health Inc. (NYSE: HIMS) had a busy week that included Q3 earnings miss, a board appointment and analyst price target changes.
globenewswire.com A $400 Billion Healthcare Opportunity: Telehealth Companies Positioned to Capitalize on a Massive Industry Shift NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Healthcare is changing, and telehealth is becoming a bigger part of that shift. Patients want easier access to doctors, hospitals are looking for more…
benzinga.com Five States Join FTC Lawsuit Alleging Hims and Hers Engaged in Deceptive and Unlawful Privacy Practices https://www.ftc.gov/news-events/news/press-releases/2026/11/five-states-join-ftc-lawsuit-alleging-hims-hers-engaged-deceptive-unlawful-privacy-practices
benzinga.com Jefferies Maintains Hold on Hims & Hers Health, Lowers Price Target to $24 Jefferies analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Hold and lowers the price target from $31 to $24.
zacks.com HIMS Q3 Earnings Call Highlights Marketing Reset and Margin Pressure Hims & Hers shifts focus on weight-loss expansion and international growth as Q3 margin pressure, subscriber losses and reduced profit guidance cloud its near-term outlook.
seekingalpha.com Hims & Hers Health: Don't Nitpick Quarterly Results Hims & Hers Health maintains robust growth prospects despite a minor Q3'26 revenue miss, leading to a market overreaction. HIMS strategically reduced marketing spend to prepare for the Eli Lilly…
benzinga.com Weight-Loss Reset Dents Hims & Hers Outlook, But Analyst Sees Opportunity Hims & Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after the company reported worse-than-expected third-quarter financial results and trimmed guidance on Monday.
benzinga.com Weight-Loss Reset Dents Hims & Hers Outlook, But Analyst Sees Opportunity Hims & Hers stock dropped after a Q3 loss and guidance cut, but Needham reaffirmed its Buy rating, seeing the post-earnings pullback as an entry point.
247wallst.com Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady A surprise quarterly loss and a weaker profit outlook are hitting Hims & Hers (NYSE:HIMS) hard. Hims & Hers stock was last at $18.77, down 18%.
schaeffersresearch.com 4 Post-Earnings Losers Drawing Unusual Options Volume Several stocks are seeing unusual options activity following their latest earnings reports, with Hims & Hers Health Inc (NYSE:HIMS), GeneDx Holdings Corp (NASDAQ:WGS), Groupon Inc (NASDAQ:GRPN), and…
247wallst.com Hims & Hers Celebrated Its Eli Lilly Deal, Then Lost a Quarter of Its Value in a Week Shares of Hims & Hers (NYSE:HIMS) traded at $18.76 at midday Tuesday. That is 18.22% lower on the session and 25.67% lower over the past week.
benzinga.com Morgan Stanley Maintains Equal-Weight on Hims & Hers Health, Lowers Price Target to $25 Morgan Stanley analyst Craig Hettenbach maintains Hims & Hers Health (NYSE:HIMS) with a Equal-Weight and lowers the price target from $28 to $25.
youtube.com HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus Marley Kayden crunches the numbers on Hims & Hers (HIMS) earnings and its worse-than-expected revenue growth. The stock plunged following the opening bell as investors question the telehealth…
benzinga.com These Analysts Revise Their Forecasts On Hims & Hers Health After Q3 Results Hims & Hers missed Q3 FY26 earnings and revenue estimates, cut guidance, and shares fell 13%; analysts revised price targets.
seekingalpha.com Hims & Hers: Why I'm Not Buying Back Yet (Rating Downgrade) Hims & Hers grew Q3 revenue 49% to $890.4 million, but adjusted EBITDA increased just $4 million to $82.4 million. Gross margin contracted from 73.8% to 57.2%, while subscribers declined 100,000…
benzinga.com Evercore ISI Group Maintains In-Line on Hims & Hers Health, Raises Price Target to $27 Evercore ISI Group analyst Mark Mahaney maintains Hims & Hers Health (NYSE:HIMS) with a In-Line and raises the price target from $24 to $27.
benzinga.com Hims & Hers Stock Feels a Pinch Tuesday: What's Happening? Hims & Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after the company reported worse-than-expected third-quarter financial results Monday after the market closed. Also, Needham…- benzinga.com Hims & Hers Stock Feels a Pinch Tuesday: What's Happening? Hims & Hers Health Inc. (NYSE: HIMS) shares are trading lower Tuesday after the company reported worse-than-expected Q3 results late Monday.
247wallst.com Hims & Hers Just Warned Investors for the Third Time This Year. CEO Andrew Dudum Calls the Subscriber Losses a Trade He'll Make ‘Every Time' Hims & Hers cut its 2026 adjusted EBITDA outlook for the third time this year, to $257 million to $277 million from February's $300 million to $375 million, posted a surprise $33 million loss, and…
fool.com Hims & Hers: 3 Key Takeaways for Long-Term Investors Revenue grew 49% year-over-year to $890 million in the third quarter. Subscribers reached 2.8 million despite a 100,000 net subscriber decline.
barrons.com Nvidia, Hims & Hers, JBS, Take-Two, and More Stocks That Explain Today's Market Hims extends a recent slump after a third-quarter loss, while JBS sinks as Chinese beef import quotas hit the meatpacking business.
benzinga.com Needham Maintains Buy on Hims & Hers Health, Lowers Price Target to $32 Needham analyst Ryan MacDonald maintains Hims & Hers Health (NYSE:HIMS) with a Buy and lowers the price target from $42 to $32.
marketbeat.com What Hims & Hers Health (HIMS) Said on Its Q3 Earnings Call Hims & Hers Health NYSE: HIMS reported third-quarter revenue growth of 49% but lost 100,000 subscribers from the prior quarter, as the digital health company held back U.S. weight-loss marketing and…
seekingalpha.com Hims & Hers Health, Inc. (HIMS) Q3 2026 Earnings Call Transcript Hims & Hers Health, Inc. ( HIMS ) Q3 2026 Earnings Call November 9, 2026 5:00 PM EST Company Participants William Newby - Senior Director of Investor Relations Andrew Dudum - Co-Founder, Chairman &…
zacks.com Hims & Hers Health (HIMS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Hims & Hers Health (HIMS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare…
zacks.com Hims & Hers Health, Inc. (HIMS) Q3 Earnings and Revenues Miss Estimates Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.06 per share a year ago.
benzinga.com Hims & Hers Health Q3 2026 Earnings Call Transcript Hims & Hers Health (NYSE:HIMS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
wsj.com Hims & Hers Narrows Sales Outlook The digital healthcare company narrowed its full-year revenue outlook after third-quarter sales came in lower than expected.
benzinga.com Hims & Hers Stock Slips Further as Q3 Print Disappoints Hims & Hers Health Inc. (NYSE:HIMS) posted its third-quarter fiscal 2026 results after Monday's closing bell, missing the Street's expectations on the top and bottom lines.
benzinga.com Hims & Hers Stock Slips Further as Q3 Print Disappoints Here's a detailed look inside the Q3 earnings report from Hims & Hers Health.- benzinga.com Hims & Hers Health Q3 EPS $(0.14) Misses $0.08 Estimate, Sales $890.373M Miss $892.888M Estimate Hims & Hers Health (NYSE:HIMS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $0.08 by 275 percent. This is a 255.56 percent decrease over earnings of…
reuters.com Hims & Hers narrows 2026 revenue forecast as margins contract Hims & Hers narrows 2026 revenue forecast as margins contract- benzinga.com Hims & Hers Health Narrows FY2026 Sales Guidance from $3.100B-$3.300B to $3.130B-$3.150B vs $3.209B Est Hims & Hers Health (NYSE:HIMS) narrows FY2026 sales outlook from $3.100 billion-$3.300 billion to $3.130 billion-$3.150 billion vs $3.209 billion estimate.
benzinga.com Hims & Hers Health Sees Q4 Sales $875.000M-$895.000M vs $953.446M Est Hims & Hers Health (NYSE:HIMS) sees Q4 sales of $875.000 million-$895.000 million vs $953.446 million analyst estimate.
businessinsider.com Andrew Huberman built a health empire on independent advice. He told us why he's now joining Hims' board. Andrew Huberman has built one of the internet's most powerful health audiences by translating science into practical advice on sleep, fitness, hormones, supplements, and longevity. Now, the Stanford…
benzinga.com Hims & Hers Stock Plunges Before Earnings: What to Watch Hims & Hers Health shares are plummeting Monday ahead of its Q3 earnings report, which is scheduled for release after the market close.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
benzinga.com Hims & Hers Short Interest Climbs to 23% Ahead of Earnings: Can the Stock Break Out? Hims & Hers Health stock has lost momentum this year. After peaking at $72.78 in 2025, it has slumped about 65% to the current $26.
fool.com Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027? Hims & Hers Health is leveraging a high-growth, subscription-based digital platform to provide personalized treatments for weight loss and sexual health. Intuitive Surgical maintains a dominant…
benzinga.com Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery Eli Lilly partners with Hims & Hers to offer Zepbound and Foundayo directly to telehealth patients with self-pay options starting at $149.
investors.com Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's obesity drugs, further entrenching itself in the GLP-1 space.
barrons.com Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement Hims & Hers stock rises after the company announces an agreement with Eli Lilly to offer the pharma giant's GLP-1s on its consumer platform.
benzinga.com Eli Lilly And Hims & Hers Partner To Expand Access To Zepbound And Orforglipron At Standard Self-Pay Prices Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platformEli Lilly and Company (NYSE:LLY) and Hims & Hers Health, Inc. (NYSE:HIMS) today announced…